Quarterly ResultAug 5, 2026, 07:47 PM
LifeMD Q2 Revenue $47.3M; FY26 Guidance Revised Down
AI Summary
LifeMD reported Q2 2026 revenue of $47.3 million, meeting its guidance, and an adjusted EBITDA loss of $3.5 million, which improved sequentially. The company saw significant gross margin expansion and subscriber growth, driven by a transition to branded GLP-1 therapies and scaling its in-house pharmacy. However, LifeMD revised its full-year 2026 revenue and adjusted EBITDA guidance downwards, citing higher-than-anticipated near-term profitability impact from strategic shifts, but expects a return to positive adjusted EBITDA in H2 2026.
Key Highlights
- Q2 2026 revenue was $47.3 million, within guidance range.
- Q2 2026 adjusted EBITDA loss was $3.5 million, improving 21% sequentially.
- Gross margin expanded 280 basis points YoY to approximately 89%.
- Weight Management Program subscribers grew to 108,000.
- Total active subscribers increased 20% YoY to 356,000.
- Exited Q2 with $25.1 million cash and no debt.
- Full-year 2026 revenue guidance revised to $205.5M-$212.5M (from $220M-$230M).
- Full-year 2026 adjusted EBITDA guidance revised to -$6.0M to breakeven (from $12M-$17M).
Price Impact
More from LFMD